We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.74B
AUM Growth
+$261M
Cap. Flow
+$250M
Cap. Flow %
14.34%
Top 10 Hldgs %
44.01%
Holding
80
New
16
Increased
10
Reduced
40
Closed
8

Top Buys

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$111M
2
BBIO icon
BridgeBio Pharma
BBIO
+$75.8M
3
STOK icon
Stoke Therapeutics
STOK
+$50.2M
4
QURE icon
uniQure
QURE
+$38.2M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$25.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$34.5M
2
ZGNX
Zogenix, Inc.
ZGNX
+$24.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.9M
4
ARGX icon
argenx
ARGX
+$15.9M
5
ANAB icon
AnaptysBio
ANAB
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$127M 7.3%
+3,122,367
New +$111M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$113M 6.51%
1,100,000
+25,000
+2% +$1.95M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$78.9M 4.53%
900,000
-25,000
-3% -$2.13M
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$76.1M 4.37%
806,150
+191,150
+31% +$16.5M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$75.2M 4.32%
2,966,108
-633,892
-18% -$12.9M
BBIO icon
6
BridgeBio Pharma
BBIO
$16.1B
$75M 4.31%
+2,780,885
New +$75.8M
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$67.9M 3.9%
1,550,000
+450,000
+41% +$25.4M
STOK icon
8
Stoke Therapeutics
STOK
$1.87B
$54.5M 3.13%
+1,869,680
New +$50.2M
AXNX
9
DELISTED
Axonics, Inc. Common Stock
AXNX
$51.3M 2.95%
1,252,495
-20,000
-2% -$562K
QURE icon
10
uniQure
QURE
$2.93B
$46.9M 2.69%
+600,000
New +$38.2M
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$46.5M 2.67%
1,177,975
+168,389
+17% +$5.92M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.5B
$46.1M 2.65%
400,000
-200,000
-33% -$23.9M
PRNB
13
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$45.2M 2.6%
1,361,898
-50,000
-4% -$1.56M
ANAB icon
14
AnaptysBio
ANAB
$1.63B
$39.5M 2.27%
700,000
-220,000
-24% -$15.8M
QTNT
15
DELISTED
Quotient Limited Ordinary Shares
QTNT
$35.5M 2.04%
95,000
-20,000
-17% -$7.14M
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.64B
$34.2M 1.96%
225,000
-75,000
-25% -$9.11M
BPMC
17
DELISTED
Blueprint Medicines
BPMC
$33M 1.9%
350,000
-100,000
-22% -$8.25M
CRSP icon
18
CRISPR Therapeutics
CRSP
$4.77B
$33M 1.89%
700,000
-200,000
-22% -$7.99M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$351M
$31.1M 1.79%
2,074,595
+374,595
+22% +$6.54M
ASND icon
20
CALL
Ascendis Pharma A/S
ASND
$16.5B
$28.8M 1.65%
+250,000
New +$29.9M
ALLK
21
DELISTED
Allakos
ALLK
$28.2M 1.62%
650,000
-100,000
-13% -$4.1M
KURA icon
22
Kura Oncology
KURA
$826M
$27.6M 1.58%
1,400,000
– –
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$25.1M 1.44%
500,000
-100,000
-17% -$4.87M
BHVN
24
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$24.1M 1.38%
+550,000
New +$31M
YMAB
25
DELISTED
Y-mAbs Therapeutics
YMAB
$22.9M 1.31%
1,000,000
+284,518
+40% +$6.53M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Cormorant Asset Management held 80 positions worth $1.74B, up 18% from $1.48B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $250M of net new capital in Q2 2019, opening 16 new positions and adding to 10 existing holdings. Its largest new stake was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was InflaRx, an estimated $34.5M trimmed.

  • Cormorant Asset Management's largest Q2 2019 buy was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.
  • Cormorant Asset Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, an estimated $25.4M increase.
  • Cormorant Asset Management's biggest Q2 2019 reduction was InflaRx, cutting an estimated $34.5M.
  • Cormorant Asset Management fully exited Zogenix, Inc. in Q2 2019, selling an estimated $24.8M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $1.74B portfolio in Q2 2019.
  • Cormorant Asset Management opened 16 new positions and closed 8 in Q2 2019.
  • Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.74B.

Based on Cormorant Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.